Published in final edited form as:

Mol Cell Endocrinol. 2009 May 25; 304(1-2): 19–29. doi:10.1016/j.mce.2009.02.018.

Endocrine disrupters as obesogens

Felix Grün¹ and Bruce Blumberg^{1,2}

¹Department of Developmental & Cell Biology, 2011 Biological Sciences 3, University of California Irvine, Irvine, CA 92697-2300

²Pharmaceutical Sciences, 2011 Biological Sciences 3, University of California Irvine, Irvine, CA 92697-2300

Abstract

The recent dramatic rise in obesity rates is an alarming global health trend that consumes an ever increasing portion of health care budgets in Western countries. The root cause of obesity is thought to be a prolonged positive energy balance. Hence, the major focus of preventative programs for obesity has been to target overeating and inadequate physical exercise. Recent research implicates environmental risk factors, including nutrient quality, stress, fetal environment and pharmaceutical or chemical exposure as relevant contributing influences. Evidence points to endocrine disrupting chemicals that interfere with the body's adipose tissue biology, endocrine hormone systems or central hypothalamic-pituitary-adrenal axis as suspects in derailing the homeostatic mechanisms important to weight control. This review highlights recent advances in our understanding of the molecular targets and mechanisms of action for these compounds and areas of future research needed to evaluate the significance of their contribution to obesity.

Introduction

Metabolite sensing and hormonal signaling balance the accumulation and mobilization of lipids from adipose tissues in response to fluctuating nutrient intake and caloric demands. However, adipose tissue is not just a passive lipid repository. Adipose depots also function as active endocrine organs that participate in the body's feedback system that fine-tunes the regulation of appetite and the metabolic integration between organs and inflammatory responses. The etiology of obesity varies, reflecting many possible points of perturbation in the regulatory pathways that maintain fat homeostasis. A multitude of factors will influence whether an individual develops obesity. Genetic, nutritional and environmental factors are known to impact hunger and satiety [1,2], basal metabolic rate [3,4], carbohydrate and lipid flux [5], and the regulation of adipocyte proliferation and differentiation and developmental programming of metabolic set points [6,7]. Recent evidence from many laboratories has shown that a variety of environmental endocrine disrupting chemicals can influence adipogenesis and obesity. *Obesogens* can be defined functionally as chemical agents that inappropriately regulate and promote lipid accumulation and adipogenesis [8]. Here we review the effects of several environmental endocrine disrupters on these pathways, discuss the data that links these "obesogens" to adipogenesis and obesity and highlight areas where future research will be helpful in ascertaining the magnitude of the risk posed by obesogen exposure.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Obesogenic effects mediated by metabolic sensors

At its most basic level the progression to obesity requires both increased adipocyte number and lipid content. A number of master transcriptional regulators are critical to the regulation of gene networks controlling intracellular lipid flux, adipocyte proliferation and differentiation. Among these are nuclear hormone receptors, particularly the peroxisome proliferator activated receptors (PPAR α , δ and γ) which function as obligate heterodimers with the 9-cis retinoic acid receptor (RXR). These heterodimers play a preeminent role, serving as metabolic ligand sensors for a variety of lipophilic hormones, dietary fatty acids and their metabolites.

Lipid agonists of RXR-PPAR α promote peroxisome proliferation and stimulate fatty acid β -oxidation [9]. Consequently, xenobiotics that target PPAR α typically act as hypolipodemic agents. In contrast, activation of RXR-PPAR γ favors lipid biosynthesis and storage, and is essential for the differentiation of resident preadipocytes and the conversion of mesenchymal progenitors to preadipocytes in adipose tissues [10]. Human allelic variants of PPAR γ produce a variety of metabolic outcomes. A hypomorphic variant of PPAR γ (Pro12Ala), is associated with lower body mass, improved insulin sensitivity and serum lipid profiles in diabetics, whereas a constitutively active allele (Pro115Gln) gives rise to obesity and insulin resistance [11,12]. Ligand modulation of PPAR γ activity causes a corresponding shift in adipogenic programs. *In vivo* treatment with PPAR γ antagonists, such as SR-202, GW9662 and JTP-426467, prevents high-fat diet induced weight gain in rodent models [13-15]. PPAR γ agonists, such as the thiazolidinediones (TZD) rosiglitazone and pioglitazone, are potent insulin sensitizing pharmaceuticals used to improve glycemic control and serum triglycerides in diabetics [16]. Unwanted, PPAR γ -mediated side effects include peripheral edema followed by persistent weight gain with prolonged use [17,18]. Therefore, TZDs are pharmaceutical obesogens that exacerbate the aspects of type 2 diabetes resulting from an overabundance of adipose tissue.

The existence of pharmaceutical obesogens predicts the existence of other chemicals with similar effects. Could endocrine disrupting chemicals target PPAR γ and phenocopy these same effects? Recent work identified members of the organotin class of persistent organic pollutants (POPs), specifically tributyltin (TBT) and triphenyltin (TPT), as highly selective and potent dual agonists of both the retinoid X receptors (RXR α , β , and γ) and PPAR γ [19,20]. Organotins are used in marine anti-fouling paints, wood catalysts, plasticizers, slimicides in industrial water systems and fungicides on foods (recently reviewed in [21]) The ability to target both receptors simultaneously should be particularly effective since adipogenic signaling can be mediated through both the RXR and PPAR γ components of the heterodimer. Receptor K_ds and transcriptional activation EC₅₀ values for TBT and TPT are in the range of 5-20 nM for both RXRs and PPAR γ [20]. *In vitro* and *in vivo* studies show that TBT drives the differentiation of murine 3T3-L1 adipocytes and modulates RXR-PPAR γ dependent pro-adipogenic gene networks in liver, adipose tissue and bone marrow [19,20,22,23]. Developmental exposure results in precocious lipid accumulation in adipose tissues and hepatic steatosis of newborn mice [20]. Long term effects following acute fetal exposure in murine models include an increase in epididymal fat mass and a trend towards body weight gain with age [20] (and unpublished data F.G./B.B.). Chronic developmental exposure in the frog *Xenopus laevis* resulted in ectopic adipocyte formation around the gonads in both males and females [20]. Similar perturbations in fatty acid homeostasis and enhanced lipid accumulation have even been observed in ramshorn snails [24]. Taken together, these studies reveal both acute and long-term adipogenic effects especially if exposure occurs during fetal development or early life.

Considering its potent effects on RXR and PPAR γ , it is obviously relevant to ask whether human populations are at risk from organotin exposure. Major environmental sources of

organotins include contaminated seafood, agricultural products, drinking water and leaching from plastics [25-29]. Organotin levels in mammals that are dependent on marine food chains have been documented at several $\mu\text{g/g}$ [30]. Studies that have directly measured organotin compounds in human tissue and blood samples are more limited. Liver samples from the late 1990s in Europe and Asia contained on average 6 and 84 ng/g wet wt respectively for total organotins with MBT and DBT as the most prevalent species; average TBT levels were less than 2 ng/g wet wt ($\sim 6 \text{ nM}$) [31,32]. However, levels of total organotins in US blood samples averaged around 21 ng/ml ; TBT comprised around 8 ng/ml ($\sim 27 \text{ nM}$) [33]. More recent analyses of European blood samples found the predominant species to be TPT at 0.09 and 0.67 ng/ml ($\sim 0.5\text{-}2 \text{ nM}$) and only occasional trace amounts of TBT [34,35]. Human adipose tissue levels remain uncharacterized. These variations in geographical and historical trends primarily reflect fragmentary data. They may also result from regional differences in the types of organotin applications and a general decline in exposure as organotins are phased out in marine paints. Notwithstanding these declines, it is probable that a portion of the general population remains vulnerable to organotin exposure at levels sufficient to activate RXRs and PPAR γ given their high affinity and the ubiquity of organotins in plastics and agricultural use.

Although the mechanistic data are not as clear-cut, further threats to lipid and adipose homeostasis are posed by other common xenobiotics with PPAR activity. These include bisphenol A from polycarbonate plastics, phthalate plasticizers used to soften PVC plastics and various perfluoroalkyl compounds (PFCs) that are widely utilized surfactants and surface repellents in consumer products. Leaching of these non-bonded phthalate and PFC additives into food and water accounts for their near ubiquitous presence in humans. Transfer of primary phthalates, such as DEHP, to food during processing lies within the range of 0.01 to 4.4 mg/kg , resulting in an estimated average daily intake of about 160 $\mu\text{g/day}$ [36,37]. Quantitation of urinary phthalate metabolites and serum levels of major PFC species (see paper by Fenton and colleagues in this issue) are in excess of several $\mu\text{g/L}$ in more than 75 % of the US population [38,39], placing them within a range of concern for endocrine disruption. Fetal or early life exposure to phthalates has been proposed to account for perturbed male reproductive system development via decreased testicular steroidal synthesis [40-43].

Receptor binding, transactivation and toxicogenomic studies confirm phthalates and PFCs can function as agonists for one or more of the PPARs, providing a mechanistic link to disturbed lipid and steroid metabolism [44-48]. Typical responses in rodents include a strong induction of hepatic peroxisome proliferation and tumorigenesis [49-52]. Di(2-ethylhexyl)phthalate (DEHP) or perfluorooctanoic acid (PFOA) increase PPAR α dependent lipid mobilization, fatty acid oxidation and adipose tissue atrophy during periods of experimental exposure [53-55]. Consequently, these hypolipidemic and anti-adipogenic effects might be expected to result in an overall reduction in adipose mass and body weight. Depressed birth weight can be induced by low to moderate prenatal exposure ($>5 \text{ mg/kg bw}$) of perfluorooctanoic acid (PFOA) in rodents [56,57] and an association between depressed birth weight and levels of PFOA in human umbilical cord blood has been documented [39]. PFOA probably exerts anorexigenic effects through a central hypothalamic mechanism that triggers a decrease in food intake in adult rodents [58]. This phenotype is not observed in PPAR α knockout animals [59].

If activating PPAR α reduces adipose mass and body weight, how might EDCs targeting PPAR α promote obesity? Several experimental observations provide insights into possible mechanisms. First, PPARs contain some of the largest and most promiscuous ligand binding pockets within the nuclear hormone receptor family, allowing PPAR agonists or their metabolites to activate multiple isoforms. Metabolites of the potent PPAR α agonist DEHP, such as mono (2-ethylhexyl) phthalate (MEHP), also activate PPAR γ thereby providing a possible route for a pro-adipogenic response. MEHP promotes 3T3-L1 adipocyte differentiation and lipid accumulation [60,61]. PPAR α -dependent stimulation of fatty acid

oxidation and peroxisomal proliferation requires continuous exposure; however, PPAR γ activators may require only single or perhaps episodic exposure to effectively drive permanent changes in adipocyte differentiation and increased cell number. Second, fetal or perinatal exposure to phthalates and PFCs disturbs transcriptional regulation of testicular steroidogenesis, decreasing androgen biosynthesis [40,62-64] and decreased androgen activity is itself obesogenic [65]. Third, low birth weight as a consequence of a poor nutritional uterine environment is an established risk factor for obesity. Hypolipidemia mediated through increased fatty acid metabolism in the developing fetus may mimic an undernourished environment that is sensed and acted upon to program long term metabolic changes. Human epidemiological data and numerous animal studies support the generalization that nutritional restriction, exposure to disparate developmental toxicants or intrauterine stress frequently results in a biphasic growth response: depressed birth weight, followed by a period of catch-up growth and an elevated risk for body weight gain and obesity in the long term [6].

Two recent studies support these contentions. Mice prenatally exposed to low levels of PFOA exhibited reduced birth weight followed by increased adipose mass and body weight after puberty [66] (see article by Fenton and colleagues in this issue). Epidemiological studies documented a positive correlation between the presence of the specific urinary phthalate metabolites, mono-benzyl phthalate (MBzP), mono-(2-ethyl-5-hydroxyhexyl) phthalate (MEHHP) and mono-(2-ethyl-5-oxohexyl) phthalate (MEOHP), with increased waist circumference in men. The metabolites mono-butyl phthalate (MBP), mono-ethyl phthalate (MEP) and mono-benzyl phthalate (MBzP) were also associated with measures of insulin resistance, a marker of metabolic syndrome [67].

Overall, it appears quite plausible that xenobiotic mimics of endogenous ligands for nutrient sensing nuclear receptors, such as the PPARs, are sufficiently potent and prevalent to inappropriately regulate transcriptional programs controlling adipogenesis. The relative contributions of developmental versus adult exposures to obesity remains to be determined; however, it is reasonable to suppose that developmental exposures would have larger and more pervasive effects.

Obesogenic effects mediated by sex steroid dysregulation

Nutrient sensing nuclear receptors are just one aspect of adipocyte regulation. Nuclear receptors for sex steroid hormones also influence adipose tissue development. Knockout models of sex steroid pathway components, e.g. FSH receptor (FORKO), aromatase (ArKO), estrogen receptor (α ERKO) and androgen receptor (ARKO), confirm a role for sex steroids in regulating adipocyte hypertrophy and hyperplasia, as well as influencing the sexually dimorphic deposition and remodeling of specific adipose sites [68-71]. Typically, sex steroids, in conjunction with peptide hormones such as growth hormone (GH), mobilize lipid stores and help to counteract the actions of insulin and cortisol on lipid accumulation. Imbalances in these hormones, therefore, are commonly observed in genetic, clinical and physiological conditions, (i.e., Cushing's syndrome, polycystic ovary syndrome (PCO), GH-deficiency, menopause, aging, alcoholism and depression), that produce dyslipidemias and obesity. The hormonal defects frequently include a relative deficiency or altered ratios in androgen/estrogen levels, lowered growth hormone secretion, hypercortisolemia and increased insulin resistance [72]. Consistent with this overall picture, anti-androgenic therapies for prostate cancer and PCO syndrome produce weight gain, whereas estrogenic hormone replacement therapy are generally protective against the changes in body fat remodeling seen with age and menopause in women [32]. Notably, dietary factors such as isoflavone phytoestrogens modulate estrogen receptor signaling and effect similar positive changes on adipose tissues. Hence, nutritional levels of genistein and daidzein reverse fat accumulation in the trunks of post-menopausal women and ovariectomized rodent models [73-76]. These effects by phytoestrogens are not seen in α ERKO

animals indicating the importance of estrogen receptor alpha (ER α) [77]. Since phytoestrogens are more potent activators of ER β than of ER α , and ER β regulates the expression of ER α [78], more work remains to be done before the relative contributions of the two ERs to phytoestrogen effects on obesity can be determined.

In contrast to its effects in adults, exposure to estrogens at critical periods of development produces obesogenic effects. For example, mice derived from dams maintained on diets with low phytoestrogen levels during pregnancy and lactation experience elevated serum estradiol levels and undergo fetal estrogenization syndrome (FES). These mice have a lower birth weight, but develop obesity, high leptin levels, and impaired glucose responses (in males), at puberty when maintained on soy supplemented chow [79]. Exposure of adult male mice to low dietary phytoestrogen levels led to decreased adipose mass, in agreement with previous animal and human studies [80].

New data on diethylstilbestrol (DES) has uncovered broadly similar obesogenic responses in rodents (See article by Newbold and colleagues in this issue). DES is a potent synthetic estrogen that was widely prescribed to women until 1971, primarily for the management of miscarriage risk. Exposure also resulted in a higher incidence of breast cancer in DES exposed mothers, and reproductive tract abnormalities and neoplasias, infertility and autoimmune disorders in daughters of DES treated mothers; sons also show abnormalities [81]. Recent studies in rodents identified weight gain as another significant change following neonatal DES exposure. Weight gain was preceded by elevated levels of leptin, adiponectin, IL-6, triglycerides and glucose, and altered insulin signaling. High doses of DES (1 mg/kg) given to neonatal female mice during the period of adipocyte differentiation initially depressed body weight, but a period of catch up growth followed until 2 months of age and a persistent enlargement of abdominal fat pads continued thereafter. Low doses of DES (10 μ g/kg) did not depress weight initially, but also led to later weight gain [82,83]. DES exposed male mice did not become obese but rather showed a dose dependent decrease in overall body weight, underscoring the important and often contrasting role gender may play in the overall response.

Obesogenic effects have also been observed with other xenoestrogenic compounds. Bisphenol A (BPA) is widely found in human populations (0.3-4.4 ng/mL in human serum [84,85]) as a consequence of leaching from polycarbonate plastics and products coated with epoxy resins (see article by Rubin and colleagues in this issue). In conjunction with insulin, BPA accelerates murine preadipocyte cell line differentiation by up-regulating adipogenic genes [86,87]. In addition to its action on the nuclear estrogen receptors, BPA can also act at low doses in a nongenomic manner via cell membrane associated estrogen receptors [88,89], directly modulate the insulin dependent PI 3-kinase/Akt kinase pathway and enhance glucose uptake [90,91]. Gestational and perinatal exposure of rodents to 0.1-1.2 mg/kg bw/day BPA in drinking water, predicted to give equivalent serum exposure levels, resulted in long term increased body weight and hyperlipidemia [92,93]. A positive correlation for human serum BPA levels with obese and PCO syndrome females has also been clinically observed [94].

Together, these data suggest that dysregulated signaling through sex steroid receptors can produce proadipogenic effects; although, the nature of the effects may depend critically on the timing of exposure and the sex of the exposed individual.

Obesogens and central integration of energy balance

Environmental pollutants targeting nuclear hormone receptors directly relevant to adipocyte biology are relatively obvious obesogen candidates. Another important class of obesogens will be those that interact with central mechanisms that coordinate the whole body response to daily nutritional fluctuations. The control over appetite exerted by the hypothalamic-pituitary-adrenal (H-P-A) axis plays a critical role to prevent hyperphagia and regulate energy

homeostasis. Could some of the numerous monoaminoergic, peptidergic and endocannabinoid signals generated by the digestive tract, adipose tissue and within the brain that are critical mediators of these circuits be potential targets for environmental obesogens? The prevalence of body weight disruption observed in various neurological disorders and their pharmaceutical treatments are suggestive of this possibility.

Neuroendocrine effects

Individuals with schizophrenia, bipolar disorder or major depression already display elevated co-morbidity for cardiovascular disease and significant clustering for metabolic syndrome risk factors, including diabetes, hypertension, dyslipidemias and obesity [95,96]. Annual prevalence rates in the US for schizophrenia (1.1%, 2.4 million), bipolar disorder (2.6 %, 5.7 million) and major depression (6.7 %, 14.8 million) reveal a sizable and growing population undergoing prescription drug treatment [97,98]. Unfortunately, a wide range of neuroactive drug regimens to treat these disorders, including tricyclic antidepressants, selective serotonin reuptake inhibitors (SSRI), atypical antipsychotics or mood stabilizers promote weight gain to the point where non-compliance with therapy is a serious concern [96,99]. The atypical antipsychotic olanzapine is a useful example to detail the magnitude of the problem. Olanzapine therapy induces weight gain of around 5 kg/year at 10 mg/day that rises in a dose dependent manner to more than 10 kg/year at 15 mg/day [100]. Prolonged use elevates serum glucose levels, promoting glucose intolerance and increases the risk of diabetes more than 4-fold compared to patients on typical antipsychotics [101,102]. Olanzapine impairs the actions of insulin, decreases glucose uptake and promotes SREBP-1 mediated adipogenesis in 3T3-L1 cells [103,104]. The diversity in chemical class and modes of action for these neuropharmaceuticals effectively illustrates the point that targeting neurotransmitter receptors, particularly subtypes that overlap with behavioral and metabolic regulatory circuits such as 5-HT(2C) and H1 receptors, is effective at eliciting obesogenic phenotypes.

Peptidergic hormones

Genetic mutation or misregulation of peptidergic hormones is also known to interfere with effective hypothalamic neuronal integration and when unbalanced lead to obesity [1]. Brain derived neuropeptide Y (NPY), orexins, agouti-related peptide (AgRP), melanin-concentrating hormone and peripheral hormones such as ghrelin are major stimulators of appetite. Intracerebroventricular injection induces feeding behavior whereas long-term infusion promotes hyperphagia and obesity [105-108]. In contrast, the postprandial release of neuroendocrine, pancreatic, gastrointestinal and adipocyte hormones, as well as nutrient metabolites, balances these signals and counteracts excessive food intake. Cholecystokinin (CCK), glucagon-like peptide 1, peptide YY, insulin, leptin, and pro-opiomelanocortin (POMC)-derived peptides are effective satiety signals when administered centrally or promote obesity when absent [1, 109-115].

Several of these peptidergic hormone factors are sensitive to modulation by nuclear receptor signaling pathways, which makes them potential transcriptional targets for endocrine disrupting chemicals. For example, estrogenic signaling intersects at several levels with hypothalamic appetite control. In clonal hypothalamic neuronal cell lines for instance, NPY and AgRP expression exhibits a complex biphasic response to estradiol, with repression or activation dependent on cellular ER α/β status [116]. Hence, direct injection of estrogen into the ventromedial hypothalamus, an area where localized estrogen synthesis overlaps with leptin receptor positive neurons, can substantially mimic the actions of leptin on orexigenic NPY and anorexigenic POMC neurons. This results in decreased food intake and general anti-obesity properties [117]. Some evidence also points to xenoestrogens as modulating peptidergic hormone expression. BPA, nonylphenol and DEHP have been reported to affect NPY expression in the midbrain [118,119] and manipulation of phytoestrogen content in rodent

chow diets significantly shifted feeding behavior (See article by Nef and colleagues in this issue).

Paradoxically, food and water intake were significantly enhanced in an adult feeding study despite an overall decrease in total body weight and adipose mass with higher phytoestrogen content [120]. An important message from this study is that weight gain does not automatically follow from increased caloric intake. Rather, it also depends on the body's adaptive responses in setting the overall metabolic rate. The associated dose-dependent reduction in leptin levels may help to explain this effect. An alternative is that other hormonal regulators, such as the gastric meal initiator hormone ghrelin, are responsible for this behavioral and metabolic sensitivity to phytoestrogens. Recent work found that ghrelin expression is positively regulated by localized estrogen synthesis and signaling in the stomach [121], although others have ascribed the primary stimulant for this changing expression to low leptin levels [122]. Experiments with 3T3-L1 cells also indicate that ghrelin may have an important role in the regulation of adipocyte cell number through its mitogenic and adipocyte differentiation properties [123].

In this context, it is interesting to ask whether endocrine disrupting organotins (such as TBT) can exert some of their obesogenic effects through disturbed estrogen receptor signaling acting on the central H-P-A axis. TBT has been extensively studied for its ability to cause imposex in marine invertebrates and some fish species [124-126]. One mechanism proposed to explain the imposex phenotype is the inhibition of aromatase, which leads to increased testosterone levels. Indeed both direct enzyme inhibition and transcriptional down regulation of aromatase by organotins are well documented in invertebrates and mammals [127-129]. Local control over estrogen production results from differential use of aromatase tissue specific promoters. While the effects of organotins on the brain specific aromatase promoter in mammals are currently unknown, aromatase in some tissues (e.g., ovarian granulosa cells), is sensitive to regulation by TBT and other RXR and PPAR γ specific ligands [130,131]. Brain isoforms and aromatase activity in fish can be either up regulated or down regulated following exposure to different levels of TBT [132,133]. Therefore, it is plausible that TBT exposure may produce a localized disruption of hypothalamic aromatase regulation leading to inappropriate peptidergic H-P-A responses. Other organotin species, such as trimethyltin (TMT) and triethyltin (TET), are well-described neurotoxins that preferentially target a subset of hippocampal neurons. TMT has been shown to induce hippocampal NPY and NPY Y2 receptor expression in the short term but this response later falls below controls due to neuronal degeneration in the lesions [134,135]. The consequences of such signaling deficits or of site-specific neuronal lesions would be particularly pronounced if exposure occurs during fetal development or in the perinatal period when hypothalamic nuclei involved in appetite regulation mature and programming of adaptive nutritional responses become entrained.

Endocannabinoid signaling

A third major circuit for appetite and body weight regulation that is a candidate for obesogenic disruption involves the endocannabinoid system (ECS) pathway (reviewed in [136]). Endogenous or dietary agonists of the cannabinoid receptor type 1 (CB1), including the lipid derivatives anandamide (AEA) and 2-arachidonyl glycerol (2-AG), have central orexigenic effects in the hypothalamus, even in satiated animals [137], and impact metabolic functions in peripheral tissues including adipose. CB1 receptors are also the target for the active component of cannabis, Δ^9 -tetrahydrocannabinol (THC). The carbohydrate cravings induced by THC from smoking marijuana are a well established behavioral response and can produce modest weight gain albeit only in the short term [138]. Smoking tobacco is also obesogenic under the appropriate conditions. Epidemiological studies of maternal smoking show that the adjusted odds ratio for obesity is between 1.5-2.0 fold greater if children were exposed during, but not

prior or after, the pregnancy [139-141]. In adults, weight gain is associated instead with cessation and nicotine withdrawal symptoms [142].

A prominent role for CB1 receptor signaling in obesity is further confirmed by knockout animals, which are leaner and resistant to diet induced obesity [143]. Polymorphisms in human CB1 and the cannabinoid metabolic enzyme FAAH tell a similar story [144,145]. Elevated endocannabinoid levels are found in obese subjects and correlate with increased visceral fat mass, suggesting that hyperactivity in cannabinoid signaling drives the obesogenic response [146,147]. Hence, pharmacological CB1 receptor antagonists, like rimonabant, are effective at reducing food intake, weight loss and eliciting favorable metabolic parameters, including reduced leptin, insulin, free fatty acids and cholesterol levels, and improving insulin resistance [148,149].

Aside from mimics of endocannabinoid lipids like THC that target CB1 receptors, could environmental factors disturb the general endocannabinoid signaling cascade? A common point of downstream convergence between the ECS and peptidergic pathways involves activation by protein phosphorylation of the master intracellular energy charge sensor, 5'-AMP-activated protein kinase (AMPK) that responds to regulate both cellular and whole body energy levels. AMPK activity modulates metabolic enzymes and transcription factors, including the PPARs, involved in balancing intracellular carbohydrate and lipid utilization. The phosphorylation status of AMPK is dependent on a wide range of metabolic and hormonal signals and exhibits reciprocal peptidergic activation in central versus peripheral tissues. In the hypothalamus, leptin and insulin are inhibitory, whereas AgRP, ghrelin and endocannabinoids activate AMPK to provoke an orexigenic response and increased sympathetic activity [150]. In contrast, leptin and adiponectin are activating in liver or adipose and antagonized by ghrelin and endocannabinoids. Hence, peripheral tissues increase lipogenic capabilities, and decrease fatty acid oxidation and expression of thermogenesis-related uncoupling proteins by both peripheral inhibition of AMPK and central sympathetic adrenergic stimulatory effects when ghrelin or endocannabinoids levels rise [151,152]. Studies with CB1 antagonists in wild type and knockout animals show that the orexigenic effects of ghrelin in the hypothalamus are dependent on a functional ECS pathway and mediated through AMPK activation [153]. Obesogenic atypical antipsychotic pharmaceuticals acting through histamine H1 receptors can also activate hypothalamic AMPK [154]. These results suggest that a broad range of environmental pollutants that perturb levels of hypothalamic peptidergic hormones, mimic endogenous lipid activators of the cannabinoid system or directly target the activity of AMPK would have the ability to drive obesogenic responses.

Two examples serve to illustrate this possibility. TBT was recently shown to activate AMPK in neuronal cell cultures [155]. Another study noted that the dioxins, 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) and 1,2,3,4,7,8-hexachlorodibenzo-p-dioxin (HxCDD), which typically induce a profound wasting syndrome at high doses (3.2 and 80 µg/kg respectively), could instead stimulate significant body weight gain in rats at low exposure levels (0.05 and 1.25 µg/kg). Peripheral AMPK activation, inhibition of phosphoenolcarboxykinase (PEPCK) activity and decreased serum levels of insulin like growth factor (IGF-1) were associated with increasing dioxin exposure dose [156]. Furthermore, dynamic expression changes in orexigenic and anorexigenic hypothalamic neuropeptides, including NPY, POMC, CART and MCH, are observed in the dioxin wasting syndrome. This effect is believed to be a consequence of aryl hydrocarbon receptor (AhR) activity on xenobiotic response elements in the promoters of these genes [157,158]. TCDD also appears to disrupt the proper processing of CCK peptide in intestinal cells [159]. Loss of tissue specific regulation for key molecular targets, such as AMPK, and activation of competing hormonal signals at different doses may explain why increasing doses of dioxin (and perhaps other potential obesogens highlighted above) lead to a switch from weight gain to loss.

Obesogens and programming of metabolic set points

Hyperphagia resulting from disruption of hypothalamic appetite centers is one way obesogens could unbalance the energy equation, but may not be sufficient to produce obesity. Outputs from the hypothalamus regulate adaptive responses that alter metabolic efficiency and establish metabolic set points. Unless this adaptive component to the basal metabolic rate is chronically exceeded or disturbed, diet induced thermogenesis and futile metabolic cycles will work to defend energy and body weight equilibrium.

A significant portion of the control over these adaptive responses is dependent on activity in the hypothalamus-pituitary-thyroid (HPT) axis that determines systemic thyroid hormone output, which exerts widespread effects on carbohydrate, lipid and protein metabolism. Local conversion of thyroxine (T₄) to the thyroid hormone receptor (TR) agonist, triiodothyronine (T₃), by type 2 deiodinase (DIO2) increases TR signaling in a tissue specific manner. Combined with sympathetic adrenergic activity, elevated TR signaling regulates expression of a number of respiratory components, including uncoupling protein-1 (UCP-1) in BAT and muscle, which reduces metabolic efficiency and increases energy expenditure [160]. Polymorphisms in UCPs are linked to specific obesity phenotypes [161-164]. An association between a combination of polymorphisms in DIO2 and PPAR γ and insulin resistance and metabolic syndrome has also been described [165]. Interestingly, a recent report ascribes the net positive energy balance elicited by the PPAR γ agonist rosiglitazone to its ability to reduce sympathetic activity to BAT and WAT, down-regulate thyroid axis signaling by reducing expression of type 2 and type 1 deiodinases, and also decrease pro-energy expenditure peptides CRH and CART in the hypothalamus [166]. Hence, depression of circulating T₄ levels, decreased localized peripheral T₃ synthesis or reduced sympathetic activity are likely to blunt adaptive responses and promote a propensity for obesity and metabolic syndrome.

In this regard, endocrine disruption by polybrominated diphenyl ethers (PBDEs) exposure is a potential concern. PBDEs are extensively used in manufactured goods as flame retardants and are frequently present in human populations. Human adipose and liver tissue samples contain respectively on average 5.3 ± 3.0 and 3.6 ± 2.1 ng/g lipid weight of PBDE congeners [167]. The adjusted odds ratio for diabetes and metabolic syndrome are respectively 1.9 and 3.1 fold in groups with the highest quartile serum levels for prevalent PBDE congeners [168]. Animal studies showed that PBDEs disturb the thyroid hormone axis, among their other effects. For instance, a 2-4 week exposure of adult rats to PBDEs was found to lower plasma thyroxine levels to 30 % and affect lipolysis and insulin stimulated glucose oxidation in isolated adipocytes [169]. Low dose PBDE exposure during gestation and lactation also decreased serum thyroxine levels and caused long-term changes in thyroid gland morphology [170-172]. A developmental toxic insult may be particularly relevant given the contributing role neonatal thyroid status has in integration of maternal environmental signals for long term metabolic and body weight programming. For example, dietary intrauterine growth restriction, quantified as low birth weight, is a strong prognostic indicator for metabolic syndrome in humans [173-175]. Neonatal hyperthyroidism is one response evoked in rats by maternal protein restriction during gestation and lactation. Subsequently, adult offspring exhibit decreased thyroid stimulating hormone (TSH) secretion, together with altered pituitary and muscle DIO2 and DIO1 expression [176]. Furthermore, neonatal hyperthyroidism mediated by direct thyroxine administration in rodents was shown to evoke secondary hypothyroidism resulting in increased adipose mass accompanied by hyperleptinemia in the long term [177]. Thus, targeting of the thyroid axis by endocrine disrupting obesogens is a plausible contributing factor for obesity.

Appropriate regulation over glucocorticoid hormone signaling is a critical component of HPA output that mediates stress responses and metabolic functions in peripheral tissues.

Glucocorticoids also play an important role in promoting adipocyte differentiation. A stressful perinatal environment, whether from unbalanced nutrition or psychosocial influences, can disrupt glucocorticoid signaling to the point that it affects long-term programming or sensitivity of central and peripheral tissues to physiological challenges [178,179]. Over-stimulation of glucocorticoid production, or perturbed local metabolism of cortisol by modulating 11 β -steroid dehydrogenase type 1 (reactivating) and type 2 (inactivating) activities, and glucocorticoid receptor (GR) signaling are implicated as contributing factors in the development of obesity [180,181]. Postnatal overfeeding of rats resulted in moderately overweight adults and was associated with increased basal and stress-induced corticosterone secretion and enhanced GR and 11 β -steroid dehydrogenase type 1 expression in visceral adipose tissue [182]. Transgenic overexpression of 11 β -HSD1 targeted to adipose tissue is sufficient to increase corticosterone levels, resulting in visceral obesity, glucose intolerance and insulin resistance. In contrast, targeted overexpression of 11 β -HSD2 protected against diet-induced obesity [183]. Intrauterine protein restriction also elevates maternal glucocorticoids, which can affect fetal development and HPA axis maturation if not adequately protected against by inactivation via placental 11 β -HSD2 [184,185].

A number of dietary and environmental agents with the ability to elevate or depress glucocorticoid signaling have now been described [186,187]. Glycyrrhetic acid, commonly used as a sweetening agent, or a synthetic derivative carbenoxolone, act as inhibitors of 11 β -HSD activities. Hypertension resulting from activation of mineralocorticoid receptors after inhibition of renal 11 β -HSD2 is observed above 2 mg/day glycyrrhetic acid in humans, equivalent to about 6 g licorice daily [188]. Furthermore, maternal gestational exposure to carbenoxolone in rats reduces birth weight, raises basal corticosterone, alters hypothalamic expression of GR and induces hyperglycemia [189,190]. Likewise, dithiocarbamates present in cosmetics and agricultural products inhibit 11 β -HSD2 [191]. The dithiocarbamate pesticide thiram is also suspected to interfere with GR ligand binding [192]. In addition, other studies report inhibition of 11 β -HSD2 by the organotin DBT [193] or TBT [194] by targeting critical cysteine residues necessary for enzymatic activity. Significant transfer and accumulation of organotins to fetal placenta, liver and brain occur with maternal dosing [195], suggesting a mechanism for localized hypercortisolism whereby the protective actions of 11 β -HSD2 in fetal tissues become compromised.

The important role that the fetal nutritional environment and stress responses exert on long term regulation of metabolic functions is becoming more evident [72]. Epigenetic programming is one established route whereby early life experiences, including exposure to suboptimal nutrients, behavioral stress or toxicants, can persist and lead to maladapted physiological responses later in life (the fetal basis of adult disease paradigm). For example, in the agouti mouse hypomethylation of a regulatory region in the agouti locus drives constitutive overexpression leading to obesity, hyperinsulinemia, diabetes and increased somatic growth [196]. Optimal maternal dietary supplementation with methionine, folic acid and choline increases methylation, reduced ectopic expression and improves outcome in offspring [197]. Imprinting is therefore sensitive to nutritional influences, but can also be affected by maternal behavior. Stress-induced behaviors in rat dams during lactation alter DNA methylation patterns in their offspring, including a region of the hippocampal promoter for GR [198]. Indeed, epigenetic imprinting of the glucocorticoid receptor and its targets is observed following perinatal nutrient restriction, exposure to a variety of hormones, including the synthetic glucocorticoid dexamethasone, or toxicant hormone mimics like benzpyrene [179, 199-201]. Depression in human mothers is also associated with an increased methylation of a GR promoter site and altered stress responses in newborns [202]. Furthermore, stress by social deprivation appears to enhance visceral fat deposition and increases the incidence of metabolic syndrome phenotypes in macaque and mouse models [203,204]. Imprinting in some cases persists across multiple subsequent generations [199,201]. This suggests that such an

epigenetic process could provide a plausible mechanism for amplifying acquired environmental effects to evoke sudden and dramatic changes in population health trends like the current obesity epidemic.

Conclusions and future directions

The progressive increase in obesity rates worldwide [205,206] suggests that a fundamental shift is occurring in how the human body integrates changing nutritional and environmental variables to maintain metabolic balance and body weight. The modern lifestyle, with its increased intake of energy-dense foods and decreased physical activity, may have pushed populations closer to the edge of a critical biological tipping point that is exposing vulnerabilities in our ability to adapt to plentiful, palatable food supplies. The obesogen hypothesis proposes that perturbations in metabolic signaling that result from exposure to novel environmental influences are superimposed on these trends of energy intake and expenditure. These obesogens include, but are not limited to endocrine disrupting compounds that alter fat cell differentiation or function and that initiate or exacerbate misregulation of homeostatic controls.

A few recurring themes are illustrated by the obesogenic examples listed above. To date most candidate environmental obesogens identified represent either chemical mimics of lipophilic hormones (e.g. bisphenol A, TBT) or inhibitors of endogenous hormone metabolism (e.g. TBT action on aromatase activity). Consequently, the sites of action are varied and the interactions complex, especially when compounds like organotins have multiple molecular targets. In many cases, dose response curves are not monotonic but exhibit changing phenotypes across dose ranges (as seen with phytoestrogens and DES). Typically high dose exposures are metabolic toxicants often leading to weight loss or growth restriction. At lower levels more similar to environmental exposures, these effects may be reversed (e.g. dioxins). Additional complexity is also introduced by timing of exposure, gender and genetic predisposition. Developmental exposure represents a limited window of heightened sensitivity wherein long-term effects distant from the initial insult can be established, and then perhaps only in a limited subset of the population. This delay in response and the experimental difficulty in establishing cause and effect for environmental factors may provide a partial answer to the underappreciated role chemical obesogens might play. The increased obesity risk due to prenatal maternal smoking certainly provides a proof-of-concept that long-term dysregulation of metabolic homeostasis is relevant at a population level. Epigenetic changes from obesogenic exposures are currently poorly understood. This will become an area for future intensive research efforts given their potential for long lasting, trans-generational effects.

Much remains undiscovered about the possible molecular mechanisms for environmental obesogens and their overall significance to the obesity epidemic. However, given the data already available on numerous obesogen candidates, the myriad chemical influences we experience daily, and the multiple targets with which they might intersect, it seems quite likely that obesogen exposure will play an important role in the current obesity epidemic. Research directed at fully understanding their mechanisms of action will be needed to fully appreciate the risks involved and possible strategies for remediation and prevention.

Acknowledgments

Work in the authors' laboratory was supported by grants from the University of California, Toxic Substances Research and Training Program (F.G.), the US Environmental Protection Agency (B.B.) and the National Institute of Environmental Health Sciences (B.B.).

References

1. Farooqi IS, O'Rahilly S. Monogenic human obesity syndromes. *Recent Prog Horm Res* 2004;59:409–24. [PubMed: 14749512]
2. Martinez-Hernandez A, Enriquez L, Moreno-Moreno MJ, Marti A. Genetics of obesity. *Public Health Nutr* 2007;10:1138–44. [PubMed: 17903322]
3. Kim B. Thyroid hormone as a determinant of energy expenditure and the basal metabolic rate. *Thyroid* 2008;18:141–4. [PubMed: 18279014]
4. Vermorel M, Lazzer S, Bitar A, Ribeyre J, Montaurier C, Fellmann N, Coudert J, Meyer M, Boirie Y. Contributing factors and variability of energy expenditure in non-obese, obese, and post-obese adolescents. *Reprod Nutr Dev* 2005;45:129–42. [PubMed: 15952420]
5. Cota D, Proulx K, Seeley RJ. The role of CNS fuel sensing in energy and glucose regulation. *Gastroenterology* 2007;132:2158–68. [PubMed: 17498509]
6. Levin BE. Metabolic imprinting: critical impact of the perinatal environment on the regulation of energy homeostasis. *Philos Trans R Soc Lond B Biol Sci* 2006;361:1107–21. [PubMed: 16815795]
7. Frontera M, Dickins B, Plagge A, Kelsey G. Imprinted genes, postnatal adaptations and enduring effects on energy homeostasis. *Adv Exp Med Biol* 2008;626:41–61. [PubMed: 18372790]
8. Grün F, Blumberg B. Perturbed nuclear receptor signaling by environmental obesogens as emerging factors in the obesity crisis. *Rev Endocr Metab Disord* 2007;8:161–71. [PubMed: 17657605]
9. Ferre P. The biology of peroxisome proliferator-activated receptors: relationship with lipid metabolism and insulin sensitivity. *Diabetes* 2004;53:S43–50. [PubMed: 14749265]
10. Rosen ED, Sarraf P, Troy AE, Bradwin G, Moore K, Milstone DS, Spiegelman BM, Mortensen RM. PPAR gamma is required for the differentiation of adipose tissue in vivo and in vitro. *Mol Cell* 1999;4:611–7. [PubMed: 10549292]
11. Ristow M, Müller-Wieland D, Pfeiffer A, Krone W, Kahn CR. Obesity associated with a mutation in a genetic regulator of adipocyte differentiation. *N Engl J Med* 1998;339:953–9. [PubMed: 9753710]
12. Hara K, Okada T, Tobe K, Yasuda K, Mori Y, Kadowaki H, Hagura R, Akanuma Y, Kimura S, Ito C, Kadowaki T. The Pro12Ala polymorphism in PPAR gamma2 may confer resistance to type 2 diabetes. *Biochem Biophys Res Commun* 2000;271:212–6. [PubMed: 10777704]
13. Rieusset J, Touri F, Michalik L, Escher P, Desvergne B, Niesor E, Wahli W. A new selective peroxisome proliferator-activated receptor gamma antagonist with antiobesity and antidiabetic activity. *Mol Endocrinol* 2002;16:2628–44. [PubMed: 12403851]
14. Nakano R, Kurosaki E, Yoshida S, Yokono M, Shimaya A, Maruyama T, Shibasaki M. Antagonism of peroxisome proliferator-activated receptor gamma prevents high-fat diet-induced obesity in vivo. *Biochem Pharmacol* 2006;72:42–52. [PubMed: 16696951]
15. Nishii J, Ito M, Ishida Y, Kakutani M, Shibata T, Matsushita M, Shindo M. JTP-426467 acts as a selective antagonist for peroxisome proliferator-activated receptor gamma in vitro and in vivo. *Diabetes Obes Metab* 2006;8:508–16. [PubMed: 16918585]
16. Goldberg RB. The new clinical trials with thiazolidinediones--DREAM, ADOPT, and CHICAGO: promises fulfilled? *Curr Opin Lipidol* 2007;18:435–42. [PubMed: 17620861]
17. Larsen TM, Toubro S, Astrup A. PPARgamma agonists in the treatment of type II diabetes: is increased fatness commensurate with long-term efficacy? *Int J Obes Relat Metab Disord* 2003;27:147–61. [PubMed: 12586994]
18. Rubenstrunk A, Hanf R, Hum DW, Fruchart JC, Staels B. Safety issues and prospects for future generations of PPAR modulators. *Biochim Biophys Acta*. 2007
19. Kanayama T, Kobayashi N, Mamiya S, Nakanishi T, Nishikawa J. Organotin compounds promote adipocyte differentiation as agonists of the peroxisome proliferator-activated receptor gamma/retinoid X receptor pathway. *Mol Pharmacol* 2005;67:766–74. [PubMed: 15611480]
20. Grün F, Watanabe H, Zamanian Z, Maeda L, Arima K, Chubacha R, Gardiner DM, Kanno J, Iguchi T, Blumberg B. Endocrine disrupting organotin compounds are potent inducers of adipogenesis in vertebrates. *Mol Endocrinol*. 2006manuscript in press
21. Nath M. Toxicity and the cardiovascular activity of organotin compounds: a review. *Applied Organometallic Chemistry* 2008;22:598–612.

22. Inadera H, Shimomura A. Environmental chemical tributyltin augments adipocyte differentiation. *Toxicol Lett*. 2005
23. Carfi M, Croera C, Ferrario D, Campi V, Bowe G, Pieters R, Gribaldo L. TBTC induces adipocyte differentiation in human bone marrow long term culture. *Toxicology*. 2008
24. Janer G, Navarro JC, Porte C. Exposure to TBT increases accumulation of lipids and alters fatty acid homeostasis in the ramshorn snail *Marisa cornuarietis*. *Comp Biochem Physiol C Toxicol Pharmacol*. 2007
25. Tsuda T, Inoue T, Kojima M, Aoki S. Daily intakes of tributyltin and triphenyltin compounds from meals. *J AOAC Int* 1995;78:941–3. [PubMed: 7580332]
26. Guerin T, Sirot V, Volatier JL, Leblanc JC. Organotin levels in seafood and its implications for health risk in high-seafood consumers. *Sci Total Environ* 2007;388:66–77. [PubMed: 17889928]
27. Ohno H, Suzuki M, Nakashima S, Aoyama T, Mitani K. Determination of organotin compounds in plastic products by GC/MS after ethyl derivatization with sodium tetraethylborate. *Shokuhin Eiseigaku Zasshi* 2002;43:208–14. [PubMed: 12436712]
28. Sadiki AI, Williams DT. A study on organotin levels in Canadian drinking water distributed through PVC pipes. *Chemosphere* 1999;38:1541–8. [PubMed: 10070734]
29. Fromme H, Mattulat A, Lahrz T, Ruden H. Occurrence of organotin compounds in house dust in Berlin (Germany). *Chemosphere* 2005;58:1377–83. [PubMed: 15686755]
30. Strand J, Jacobsen JA. Accumulation and trophic transfer of organotins in a marine food web from the Danish coastal waters. *Sci Total Environ* 2005;350:72–85. [PubMed: 16227074]
31. Takahashi S, Mukai H, Tanabe S, Sakayama K, Miyazaki T, Masuno H. Butyltin residues in livers of humans and wild terrestrial mammals and in plastic products. *Environ Pollut* 1999;106:213–8. [PubMed: 15093048]
32. Jones ME, Thorburn AW, Britt KL, Hewitt KN, Wreford NG, Proietto J, Oz OK, Leury BJ, Robertson KM, Yao S, Simpson ER. Aromatase-deficient (ArKO) mice have a phenotype of increased adiposity. *Proc Natl Acad Sci U S A* 2000;97:12735–40. [PubMed: 11070087]
33. Kannan K, Senthilkumar K, Giesy J. Occurrence of butyltin compounds in human blood. *Environ Sci Tech* 1999;33:1776–9.
34. Rantakokko P, Turunen A, Verkasalo PK, Kiviranta H, Mannisto S, Vartiainen T. Blood levels of organotin compounds and their relation to fish consumption in Finland. *Sci Total Environ*. 2008
35. Lo S, Allera A, Albers P, Heimbrecht J, Jantzen E, Klingmuller D, Steckelbroeck S. Dithioerythritol (DTE) prevents inhibitory effects of triphenyltin (TPT) on the key enzymes of the human sex steroid hormone metabolism. *J Steroid Biochem Mol Biol* 2003;84:569–76. [PubMed: 12767282]
36. Tsumura Y, Ishimitsu S, Saito I, Sakai H, Tsuchida Y, Tonogai Y. Estimated daily intake of plasticizers in 1-week duplicate diet samples following regulation of DEHP-containing PVC gloves in Japan. *Food Addit Contam* 2003;20:317–24. [PubMed: 12775472]
37. Tsumura Y, Ishimitsu S, Saito I, Sakai H, Kobayashi Y, Tonogai Y. Eleven phthalate esters and di (2-ethylhexyl) adipate in one-week duplicate diet samples obtained from hospitals and their estimated daily intake. *Food Addit Contam* 2001;18:449–60. [PubMed: 11358187]
38. Centers for Disease Control and Prevention. Third National Report on Human Exposure to Environmental Chemicals. Atlanta (GA): CDC; 2005.
39. Apelberg BJ, Witter FR, Herbstman JB, Calafat AM, Halden RU, Needham LL, Goldman LR. Cord serum concentrations of perfluorooctane sulfonate (PFOS) and perfluorooctanoate (PFOA) in relation to weight and size at birth. *Environ Health Perspect* 2007;115:1670–6. [PubMed: 18008002]
40. Parks LG, Ostby JS, Lambright CR, Abbott BD, Klinefelter GR, Barlow NJ, Gray LE Jr. The plasticizer diethylhexyl phthalate induces malformations by decreasing fetal testosterone synthesis during sexual differentiation in the male rat. *Toxicol Sci* 2000;58:339–49. [PubMed: 11099646]
41. Fisher JS. Environmental anti-androgens and male reproductive health: focus on phthalates and testicular dysgenesis syndrome. *Reproduction* 2004;127:305–15. [PubMed: 15016950]
42. Swan SH, Main KM, Liu F, Stewart SL, Kruse RL, Calafat AM, Mao CS, Redmon JB, Ternand CL, Sullivan S, Teague JL. Decrease in anogenital distance among male infants with prenatal phthalate exposure. *Environ Health Perspect* 2005;113:1056–61. [PubMed: 16079079]
43. Main KM, Mortensen GK, Kaleva MM, Boisen KA, Damgaard IN, Chellakooty M, Schmidt IM, Suomi AM, Virtanen HE, Petersen DV, Andersson AM, Toppari J, Skakkebaek NE. Human breast

- milk contamination with phthalates and alterations of endogenous reproductive hormones in infants three months of age. *Environ Health Perspect* 2006;114:270–6. [PubMed: 16451866]
44. Bell FP. Effects of phthalate esters on lipid metabolism in various tissues, cells and organelles in mammals. *Environ Health Perspect* 1982;45:41–50. [PubMed: 7140695]
 45. Lapinskas PJ, Brown S, Leesnitzer LM, Blanchard S, Swanson C, Cattley RC, Corton JC. Role of PPARalpha in mediating the effects of phthalates and metabolites in the liver. *Toxicology* 2005;207:149–63. [PubMed: 15590130]
 46. Maloney EK, Waxman DJ. trans-Activation of PPARalpha and PPARGgamma by structurally diverse environmental chemicals. *Toxicol Appl Pharmacol* 1999;161:209–18. [PubMed: 10581215]
 47. Rosen MB, Lee JS, Ren H, Vallanat B, Liu J, Waalkes MP, Abbott BD, Lau C, Corton JC. Toxicogenomic dissection of the perfluorooctanoic acid transcript profile in mouse liver: evidence for the involvement of nuclear receptors PPAR alpha and CAR. *Toxicol Sci* 2008;103:46–56. [PubMed: 18281256]
 48. Vanden Heuvel JP, Thompson JT, Frame SR, Gillies PJ. Differential activation of nuclear receptors by perfluorinated fatty acid analogs and natural fatty acids: a comparison of human, mouse, and rat peroxisome proliferator-activated receptor-alpha, -beta, and -gamma, liver X receptor-beta, and retinoid X receptor-alpha. *Toxicol Sci* 2006;92:476–89. [PubMed: 16731579]
 49. Rusyn I, Peters JM, Cunningham ML. Modes of action and species-specific effects of di-(2-ethylhexyl)phthalate in the liver. *Crit Rev Toxicol* 2006;36:459–79. [PubMed: 16954067]
 50. Warren JR, Lalwani ND, Reddy JK. Phthalate esters as peroxisome proliferator carcinogens. *Environ Health Perspect* 1982;45:35–40. [PubMed: 6754363]
 51. Abdellatif AG, Preat V, Taper HS, Roberfroid M. The modulation of rat liver carcinogenesis by perfluorooctanoic acid, a peroxisome proliferator. *Toxicol Appl Pharmacol* 1991;111:530–7. [PubMed: 1684073]
 52. Ikeda T, Aiba K, Fukuda K, Tanaka M. The induction of peroxisome proliferation in rat liver by perfluorinated fatty acids, metabolically inert derivatives of fatty acids. *J Biochem* 1985;98:475–82. [PubMed: 4066651]
 53. Itsuki-Yoneda A, Kimoto M, Tsuji H, Hiemori M, Yamashita H. Effect of a hypolipidemic drug, Di (2-ethylhexyl) phthalate, on mRNA-expression associated fatty acid and acetate metabolism in rat tissues. *Biosci Biotechnol Biochem* 2007;71:414–20. [PubMed: 17284823]
 54. Xie Y, Yang Q, Nelson BD, DePierre JW. Characterization of the adipose tissue atrophy induced by peroxisome proliferators in mice. *Lipids* 2002;37:139–46. [PubMed: 11908906]
 55. Xie Y, Yang Q, Nelson BD, DePierre JW. The relationship between liver peroxisome proliferation and adipose tissue atrophy induced by peroxisome proliferator exposure and withdrawal in mice. *Biochem Pharmacol* 2003;66:749–56. [PubMed: 12948855]
 56. Abbott BD, Wolf CJ, Schmid JE, Das KP, Zehr RD, Helfant L, Nakayama S, Lindstrom AB, Strynar MJ, Lau C. Perfluorooctanoic acid induced developmental toxicity in the mouse is dependent on expression of peroxisome proliferator activated receptor-alpha. *Toxicol Sci* 2007;98:571–81. [PubMed: 17488742]
 57. Wolf CJ, Fenton SE, Schmid JE, Calafat AM, Kuklenyik Z, Bryant XA, Thibodeaux J, Das KP, White SS, Lau CS, Abbott BD. Developmental toxicity of perfluorooctanoic acid in the CD-1 mouse after cross-foster and restricted gestational exposures. *Toxicol Sci* 2007;95:462–73. [PubMed: 17098816]
 58. Asakawa A, Toyoshima M, Fujimiya M, Harada K, Ataka K, Inoue K, Koizumi A. Perfluorooctane sulfonate influences feeding behavior and gut motility via the hypothalamus. *Int J Mol Med* 2007;19:733–9. [PubMed: 17390077]
 59. Asakawa A, Toyoshima M, Harada KH, Fujimiya M, Inoue K, Koizumi A. The ubiquitous environmental pollutant perfluorooctanoic acid inhibits feeding behavior via peroxisome proliferator-activated receptor-alpha. *Int J Mol Med* 2008;21:439–45. [PubMed: 18360689]
 60. Hurst CH, Waxman DJ. Activation of PPARalpha and PPARGgamma by environmental phthalate monoesters. *Toxicol Sci* 2003;74:297–308. [PubMed: 12805656]
 61. Feige JN, Gelman L, Rossi D, Zoete V, Metivier R, Tudor C, Anghel SI, Grosdidier A, Lathion C, Engelborghs Y, Michielin O, Wahli W, Desvergne B. The endocrine disruptor monoethyl-hexyl-phthalate is a selective peroxisome proliferator-activated receptor gamma modulator that promotes adipogenesis. *J Biol Chem* 2007;282:19152–66. [PubMed: 17468099]

62. Gray LE Jr, Ostby J, Furr J, Price M, Veeramachaneni DN, Parks L. Perinatal exposure to the phthalates DEHP, BBP, and DINP, but not DEP, DMP, or DOTP, alters sexual differentiation of the male rat. *Toxicol Sci* 2000;58:350–65. [PubMed: 11099647]
63. Jarfelt K, Dalgaard M, Hass U, Borch J, Jacobsen H, Ladefoged O. Antiandrogenic effects in male rats perinatally exposed to a mixture of di(2-ethylhexyl) phthalate and di(2-ethylhexyl) adipate. *Reprod Toxicol* 2005;19:505–15. [PubMed: 15749265]
64. Jensen AA, Leffers H. Emerging endocrine disruptors: perfluoroalkylated substances. *Int J Androl* 2008;31:161–9. [PubMed: 18315716]
65. Braga-Basaria M, Dobs AS, Muller DC, Carducci MA, John M, Egan J, Basaria S. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. *J Clin Oncol* 2006;24:3979–83. [PubMed: 16921050]
66. Betts KS. Perfluoroalkyl acids: what is the evidence telling us? *Environ Health Perspect* 2007;115:A250–256. [PubMed: 17520044]
67. Stahlhut RW, van Wijgaarden E, Dye TD, Cook S, Swan SH. Concentrations of urinary phthalate metabolites are associated with increased waist circumference and insulin resistance in adult U.S. males. *Environ Health Perspect* 2007;115:876–882. [PubMed: 17589594]
68. Danilovich N, Babu PS, Xing W, Gerdes M, Krishnamurthy H, Sairam MR. Estrogen deficiency, obesity, and skeletal abnormalities in follicle-stimulating hormone receptor knockout (FORKO) female mice. *Endocrinology* 2000;141:4295–308. [PubMed: 11089565]
69. Murata Y, Robertson KM, Jones ME, Simpson ER. Effect of estrogen deficiency in the male: the ArKO mouse model. *Mol Cell Endocrinol* 2002;193:7–12. [PubMed: 12160996]
70. Heine PA, Taylor JA, Iwamoto GA, Lubahn DB, Cooke PS. Increased adipose tissue in male and female estrogen receptor-alpha knockout mice. *Proc Natl Acad Sci U S A* 2000;97:12729–34. [PubMed: 11070086]
71. Matsumoto T, Takeyama K, Sato T, Kato S. Androgen receptor functions from reverse genetic models. *J Steroid Biochem Mol Biol* 2003;85:95–9. [PubMed: 12943692]
72. Bjorntorp P. Body fat distribution, insulin resistance, and metabolic diseases. *Nutrition* 1997;13:795–803. [PubMed: 9290093]
73. Naaz A, Yellayi S, Zakroczymski MA, Bunick D, Doerge DR, Lubahn DB, Helferich WG, Cooke PS. The soy isoflavone genistein decreases adipose deposition in mice. *Endocrinology* 2003;144:3315–20. [PubMed: 12865308]
74. Kim HK, Nelson-Dooley C, Della-Fera MA, Yang JY, Zhang W, Duan J, Hartzell DL, Hamrick MW, Baile CA. Genistein decreases food intake, body weight, and fat pad weight and causes adipose tissue apoptosis in ovariectomized female mice. *J Nutr* 2006;136:409–14. [PubMed: 16424120]
75. Goodman-Gruen D, Kritiz-Silverstein D. Usual dietary isoflavone intake and body composition in postmenopausal women. *Menopause* 2003;10:427–32. [PubMed: 14501604]
76. Wu J, Oka J, Tabata I, Higuchi M, Toda T, Fuku N, Ezaki J, Sugiyama F, Uchiyama S, Yamada K, Ishimi Y. Effects of isoflavone and exercise on BMD and fat mass in postmenopausal Japanese women: a 1-year randomized placebo-controlled trial. *J Bone Miner Res* 2006;21:780–9. [PubMed: 16734394]
77. Cooke PS, Naaz A. Effects of estrogens and the phytoestrogen genistein on adipogenesis and lipogenesis in males and females. *Birth Defects Res A Clin Mol Teratol* 2005;73:472–473. [PubMed: 15959885]
78. Henley DV, Korach KS. Endocrine-disrupting chemicals use distinct mechanisms of action to modulate endocrine system function. *Endocrinology* 2006;147:S25–32. [PubMed: 16690802]
79. Ruhlen RL, Howdeshell KL, Mao J, Taylor JA, Bronson FH, Newbold RR, Welshons WV, vom Saal FS. Low phytoestrogen levels in feed increase fetal serum estradiol resulting in the “fetal estrogenization syndrome” and obesity in CD-1 mice. *Environ Health Perspect* 2008;116:322–8. [PubMed: 18335098]
80. Penza M, Montani C, Romani A, Vignolini P, Pampaloni B, Tanini A, Brandi ML, Alonso-Magdalena P, Nadal A, Ottobriani L, Parolini O, Bignotti E, Calza S, Maggi A, Grigolato PG, Di Lorenzo D. Genistein affects adipose tissue deposition in a dose-dependent and gender-specific manner. *Endocrinology* 2006;147:5740–51. [PubMed: 16959845]

81. Rubin MM. Antenatal exposure to DES: lessons learned...future concerns. *Obstet Gynecol Surv* 2007;62:548–55. [PubMed: 17634156]
82. Newbold RR, Padilla-Banks E, Snyder RJ, Jefferson WN. Perinatal exposure to environmental estrogens and the development of obesity. *Mol Nutr Food Res* 2007;51:912–7. [PubMed: 17604389]
83. Newbold RR, Padilla-Banks E, Snyder RJ, Phillips TM, Jefferson WN. Developmental exposure to endocrine disruptors and the obesity epidemic. *Reprod Toxicol* 2007;23:290–6. [PubMed: 17321108]
84. Inoue K, Kato K, Yoshimura Y, Makino T, Nakazawa H. Determination of bisphenol A in human serum by high-performance liquid chromatography with multi-electrode electrochemical detection. *J Chromatogr B Biomed Sci Appl* 2000;749:17–23. [PubMed: 11129074]
85. vom Saal FS, Akingbemi BT, Belcher SM, Birnbaum LS, Crain DA, Eriksen M, Farabollini F, Guillette LJ Jr, Hauser R, Heindel JJ, Ho SM, Hunt PA, Iguchi T, Jobling S, Kanno J, Keri RA, Knudsen KE, Laufer H, LeBlanc GA, Marcus M, McLachlan JA, Myers JP, Nadal A, Newbold RR, Olea N, Prins GS, Richter CA, Rubin BS, Sonnenschein C, Soto AM, Talsness CE, Vandenberg JG, Vandenberg LN, Walser-Kuntz DR, Watson CS, Welshons WV, Wetherill Y, Zoeller RT. Chapel Hill bisphenol A expert panel consensus statement: integration of mechanisms, effects in animals and potential to impact human health at current levels of exposure. *Reprod Toxicol* 2007;24:131–8. [PubMed: 17768031]
86. Masuno H, Kidani T, Sekiya K, Sakayama K, Shiosaka T, Yamamoto H, Honda K. Bisphenol A in combination with insulin can accelerate the conversion of 3T3-L1 fibroblasts to adipocytes. *J Lipid Res* 2002;43:676–84. [PubMed: 11971937]
87. Phrakonkham P, Viengchareun S, Belloir C, Lombes M, Artur Y, Canivenc-Lavier MC. Dietary xenoestrogens differentially impair 3T3-L1 preadipocyte differentiation and persistently affect leptin synthesis. *J Steroid Biochem Mol Biol*. 2008
88. Thomas P, Dong J. Binding and activation of the seven-transmembrane estrogen receptor GPR30 by environmental estrogens: a potential novel mechanism of endocrine disruption. *J Steroid Biochem Mol Biol* 2006;102:175–9. [PubMed: 17088055]
89. Watson CS, Bulayeva NN, Wozniak AL, Alyea RA. Xenoestrogens are potent activators of nongenomic estrogenic responses. *Steroids* 2007;72:124–34. [PubMed: 17174995]
90. Masuno H, Iwanami J, Kidani T, Sakayama K, Honda K. Bisphenol a accelerates terminal differentiation of 3T3-L1 cells into adipocytes through the phosphatidylinositol 3-kinase pathway. *Toxicol Sci* 2005;84:319–27. [PubMed: 15659569]
91. Sakurai K, Kawazuma M, Adachi T, Harigaya T, Saito Y, Hashimoto N, Mori C. Bisphenol A affects glucose transport in mouse 3T3-F442A adipocytes. *Br J Pharmacol* 2004;141:209–14. [PubMed: 14707028]
92. Rubin BS, Murray MK, Damassa DA, King JC, Soto AM. Perinatal exposure to low doses of bisphenol A affects body weight, patterns of estrous cyclicity, and plasma LH levels. *Environ Health Perspect* 2001;109:675–80. [PubMed: 11485865]
93. Miyawaki J, Sakayama K, Kato H, Yamamoto H, Masuno H. Perinatal and postnatal exposure to bisphenol a increases adipose tissue mass and serum cholesterol level in mice. *J Atheroscler Thromb* 2007;14:245–52. [PubMed: 17938543]
94. Takeuchi T, Tsutsumi O, Ikezuki Y, Takai Y, Taketani Y. Positive relationship between androgen and the endocrine disruptor, bisphenol A, in normal women and women with ovarian dysfunction. *Endocr J* 2004;51:165–9. [PubMed: 15118266]
95. Casey DE. Metabolic issues and cardiovascular disease in patients with psychiatric disorders. *Am J Med* 2005;118:15S–22S. [PubMed: 15903291]
96. Ruetsch O, Viala A, Bardou H, Martin P, Vacheron MN. Psychotropic drugs induced weight gain: a review of the literature concerning epidemiological data, mechanisms and management. *Encephale* 2005;31:507–16. [PubMed: 16389718]
97. Kessler RC, Chiu WT, Demler O, Merikangas KR, Walters EE. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. *Arch Gen Psychiatry* 2005;62:617–27. [PubMed: 15939839]
98. Kessler RC, Berglund P, Demler O, Jin R, Koretz D, Merikangas KR, Rush AJ, Walters EE, Wang PS. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). *Jama* 2003;289:3095–105. [PubMed: 12813115]

99. Baptista T, De Mendoza S, Beaulieu S, Bermudez A, Martinez M. The metabolic syndrome during atypical antipsychotic drug treatment: mechanisms and management. *Metab Syndr Relat Disord* 2004;2:290–307. [PubMed: 18370698]
100. Nemeroff CB. Dosing the antipsychotic medication olanzapine. *J Clin Psychiatry* 1997;58:45–9. [PubMed: 9265916]
101. Wirshing DA, Boyd JA, Meng LR, Ballon JS, Marder SR, Wirshing WC. The effects of novel antipsychotics on glucose and lipid levels. *J Clin Psychiatry* 2002;63:856–65. [PubMed: 12416594]
102. Koro CE, Fedder DO, L'Italien GJ, Weiss SS, Magder LS, Kreyenbuhl J, Revicki DA, Buchanan RW. Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study. *Bmj* 2002;325:243. [PubMed: 12153919]
103. Yang LH, Chen TM, Yu ST, Chen YH. Olanzapine induces SREBP-1-related adipogenesis in 3T3-L1 cells. *Pharmacol Res* 2007;56:202–8. [PubMed: 17651982]
104. Vestri HS, Maianu L, Moellering DR, Garvey WT. Atypical antipsychotic drugs directly impair insulin action in adipocytes: effects on glucose transport, lipogenesis, and antilipolysis. *Neuropsychopharmacology* 2007;32:765–72. [PubMed: 16823387]
105. Raposinho PD, Pierroz DD, Broqua P, White RB, Pedrazzini T, Aubert ML. Chronic administration of neuropeptide Y into the lateral ventricle of C57BL/6J male mice produces an obesity syndrome including hyperphagia, hyperleptinemia, insulin resistance, and hypogonadism. *Mol Cell Endocrinol* 2001;185:195–204. [PubMed: 11738809]
106. Sakurai T, Amemiya A, Ishii M, Matsuzaki I, Chemelli RM, Tanaka H, Williams SC, Richardson JA, Kozlowski GP, Wilson S, Arch JR, Buckingham RE, Haynes AC, Carr SA, Annan RS, McNulty DE, Liu WS, Terrett JA, Elshourbagy NA, Bergsma DJ, Yanagisawa M. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. *Cell* 1998;92:573–85. [PubMed: 9491897]
107. Klebig ML, Wilkinson JE, Geisler JG, Woychik RP. Ectopic expression of the agouti gene in transgenic mice causes obesity, features of type II diabetes, and yellow fur. *Proc Natl Acad Sci U S A* 1995;92:4728–32. [PubMed: 7761391]
108. Tschöp M, Smiley DL, Heiman ML. Ghrelin induces adiposity in rodents. *Nature* 2000;407:908–13. [PubMed: 11057670]
109. Corp ES, Curcio M, Gibbs J, Smith GP. The effect of centrally administered CCK-receptor antagonists on food intake in rats. *Physiol Behav* 1997;61:823–7. [PubMed: 9177553]
110. Turton MD, O'Shea D, Gunn I, Beak SA, Edwards CM, Meeran K, Choi SJ, Taylor GM, Heath MM, Lambert PD, Wilding JP, Smith DM, Ghatei MA, Herbert J, Bloom SR. A role for glucagon-like peptide-1 in the central regulation of feeding. *Nature* 1996;379:69–72. [PubMed: 8538742]
111. Batterham RL, Cohen MA, Ellis SM, Le Roux CW, Withers DJ, Frost GS, Ghatei MA, Bloom SR. Inhibition of food intake in obese subjects by peptide YY3-36. *N Engl J Med* 2003;349:941–8. [PubMed: 12954742]
112. Sipols AJ, Bayer J, Bennett R, Figlewicz DP. Intraventricular insulin decreases kappa opioid-mediated sucrose intake in rats. *Peptides* 2002;23:2181–7. [PubMed: 12535697]
113. Campfield LA, Smith FJ, Guisez Y, Devos R, Burn P. Recombinant mouse OB protein: evidence for a peripheral signal linking adiposity and central neural networks. *Science* 1995;269:546–9. [PubMed: 7624778]
114. Montague CT, Farooqi IS, Whitehead JP, Soos MA, Rau H, Wareham NJ, Sewter CP, Digby JE, Mohammed SN, Hurst JA, Cheetham CH, Earley AR, Barnett AH, Prins JB, O'Rahilly S. Congenital leptin deficiency is associated with severe early-onset obesity in humans. *Nature* 1997;387:903–8. [PubMed: 9202122]
115. Krude H, Biebermann H, Gruters A. Mutations in the human proopiomelanocortin gene. *Ann N Y Acad Sci* 2003;994:233–9. [PubMed: 12851321]
116. Titolo D, Cai F, Belsham DD. Coordinate regulation of neuropeptide Y and agouti-related peptide gene expression by estrogen depends on the ratio of estrogen receptor (ER) alpha to ERbeta in clonal hypothalamic neurons. *Mol Endocrinol* 2006;20:2080–92. [PubMed: 16675543]
117. Gao Q, Horvath TL. Cross-talk between estrogen and leptin signaling in the hypothalamus. *Am J Physiol Endocrinol Metab* 2008;294:E817–26. [PubMed: 18334610]

118. Masuo Y, Morita M, Oka S, Ishido M. Motor hyperactivity caused by a deficit in dopaminergic neurons and the effects of endocrine disruptors: a study inspired by the physiological roles of PACAP in the brain. *Regul Pept* 2004;123:225–34. [PubMed: 15518916]
119. Masuo Y, Ishido M, Morita M, Oka S. Effects of neonatal treatment with 6-hydroxydopamine and endocrine disruptors on motor activity and gene expression in rats. *Neural Plast* 2004;11:59–76. [PubMed: 15303306]
120. Lephart ED, Setchell KD, Handa RJ, Lund TD. Behavioral effects of endocrine-disrupting substances: phytoestrogens. *Ilar J* 2004;45:443–54. [PubMed: 15454683]
121. Sakata I, Tanaka T, Yamazaki M, Tanizaki T, Zheng Z, Sakai T. Gastric estrogen directly induces ghrelin expression and production in the rat stomach. *J Endocrinol* 2006;190:749–57. [PubMed: 17003276]
122. Zhao Z, Sakata I, Okubo Y, Koike K, Kangawa K, Sakai T. Gastric leptin, but not estrogen and somatostatin, contributes to the elevation of ghrelin mRNA expression level in fasted rats. *J Endocrinol* 2008;196:529–38. [PubMed: 18310448]
123. Kim MS, Yoon CY, Jang PG, Park YJ, Shin CS, Park HS, Ryu JW, Pak YK, Park JY, Lee KU, Kim SY, Lee HK, Kim YB, Park KS. The mitogenic and antiapoptotic actions of ghrelin in 3T3-L1 adipocytes. *Mol Endocrinol* 2004;18:2291–301. [PubMed: 15178745]
124. Boyer JJ. Toxicity of dibutyltin, tributyltin and other organotin compounds to humans and to experimental animals. *Toxicology* 1989;55:253–98. [PubMed: 2655175]
125. Shimasaki Y, Kitano T, Oshima Y, Inoue S, Imada N, Honjo T. Tributyltin causes masculinization in fish. *Environ Toxicol Chem* 2003;22:141–4. [PubMed: 12503757]
126. McAllister BG, Kime DE. Early life exposure to environmental levels of the aromatase inhibitor tributyltin causes masculinisation and irreversible sperm damage in zebrafish (*Danio rerio*). *Aquat Toxicol* 2003;65:309–16. [PubMed: 13678849]
127. Heidrich DD, Steckelbroeck S, Klingmüller D. Inhibition of human cytochrome P450 aromatase activity by butyltins. *Steroids* 2001;66:763–9. [PubMed: 11522339]
128. Cooke GM. Effect of organotins on human aromatase activity in vitro. *Toxicol Lett* 2002;126:121–30. [PubMed: 11751016]
129. Horiguchi T. Masculinization of female gastropod mollusks induced by organotin compounds, focusing on mechanism of actions of tributyltin and triphenyltin for development of imposex. *Environ Sci* 2006;13:77–87. [PubMed: 16788559]
130. Mu YM, Yanase T, Nishi Y, Waseda N, Oda T, Tanaka A, Takayanagi R, Nawata H. Insulin sensitizer, troglitazone, directly inhibits aromatase activity in human ovarian granulosa cells. *Biochem Biophys Res Commun* 2000;271:710–3. [PubMed: 10814527]
131. Saitoh M, Yanase T, Morinaga H, Tanabe M, Mu YM, Nishi Y, Nomura M, Okabe T, Goto K, Takayanagi R, Nawata H. Tributyltin or triphenyltin inhibits aromatase activity in the human granulosa-like tumor cell line KGN. *Biochem Biophys Res Commun* 2001;289:198–204. [PubMed: 11708799]
132. Lyssimachou A, Jenssen BM, Arukwe A. Brain cytochrome P450 aromatase gene isoforms and activity levels in atlantic salmon after waterborne exposure to nominal environmental concentrations of the pharmaceutical ethynylestradiol and antifoulant tributyltin. *Toxicol Sci* 2006;91:82–92. [PubMed: 16484284]
133. Cheshenko K, Pakdel F, Segner H, Kah O, Eggen RI. Interference of endocrine disrupting chemicals with aromatase CYP19 expression or activity, and consequences for reproduction of teleost fish. *Gen Comp Endocrinol* 2008;155:31–62. [PubMed: 17459383]
134. Ishikura N, Tsunashima K, Watanabe K, Nishimura T, Minabe Y, Kato N. Neuropeptide Y and somatostatin participate differently in the seizure-generating mechanisms following trimethyltin-induced hippocampal damage. *Neurosci Res* 2002;44:237–48. [PubMed: 12413652]
135. Sadamatsu M, Tsunashima K, Schwarzer C, Takahashi Y, Kato N, Sperk G. Trimethyltin-induced expression of neuropeptide Y Y2 receptors in rat dentate gyrus. *Neurotoxicol Teratol* 1998;20:607–10. [PubMed: 9831121]
136. Arias Horcujadas F. Cannabinoids in eating disorders and obesity. *Mol Neurobiol* 2007;36:113–28. [PubMed: 17952656]

137. Williams CM, Kirkham TC. Observational analysis of feeding induced by Delta9-THC and anandamide. *Physiol Behav* 2002;76:241–50. [PubMed: 12044596]
138. Greenberg I, Kuehnle J, Mendelson JH, Bernstein JG. Effects of marihuana use on body weight and caloric intake in humans. *Psychopharmacology (Berl)* 1976;49:79–84. [PubMed: 822452]
139. Al Mamun A, Lawlor DA, Alati R, O'Callaghan MJ, Williams GM, Najman JM. Does maternal smoking during pregnancy have a direct effect on future offspring obesity? Evidence from a prospective birth cohort study. *Am J Epidemiol* 2006;164:317–25. [PubMed: 16775040]
140. Oken E, Huh SY, Taveras EM, Rich-Edwards JW, Gillman MW. Associations of maternal prenatal smoking with child adiposity and blood pressure. *Obes Res* 2005;13:2021–8. [PubMed: 16339135]
141. Power C, Jefferis BJ. Fetal environment and subsequent obesity: a study of maternal smoking. *Int J Epidemiol* 2002;31:413–9. [PubMed: 11980805]
142. Yun AJ, Bazar KA, Lee PY, Gerber A, Daniel SM. The smoking gun: many conditions associated with tobacco exposure may be attributable to paradoxical compensatory autonomic responses to nicotine. *Med Hypotheses* 2005;64:1073–9. [PubMed: 15823687]
143. Ravinet Trillou C, Delgorge C, Menet C, Arnone M, Soubrie P. CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity. *Int J Obes Relat Metab Disord* 2004;28:640–8. [PubMed: 14770190]
144. Gazzerri P, Caruso MG, Notarnicola M, Misciagna G, Guerra V, Laezza C, Bifulco M. Association between cannabinoid type-1 receptor polymorphism and body mass index in a southern Italian population. *Int J Obes (Lond)* 2007;31:908–12. [PubMed: 17160086]
145. Sipe JC, Waalen J, Gerber A, Beutler E. Overweight and obesity associated with a missense polymorphism in fatty acid amide hydrolase (FAAH). *Int J Obes (Lond)* 2005;29:755–9. [PubMed: 15809662]
146. Engeli S, Bohnke J, Feldpausch M, Gorzelnik K, Janke J, Batkai S, Pacher P, Harvey-White J, Luft FC, Sharma AM, Jordan J. Activation of the peripheral endocannabinoid system in human obesity. *Diabetes* 2005;54:2838–43. [PubMed: 16186383]
147. Bluher M, Engeli S, Klöting N, Berndt J, Fasshauer M, Batkai S, Pacher P, Schon MR, Jordan J, Stumvoll M. Dysregulation of the peripheral and adipose tissue endocannabinoid system in human abdominal obesity. *Diabetes* 2006;55:3053–60. [PubMed: 17065342]
148. Colombo G, Agabio R, Diaz G, Lobina C, Reali R, Gessa GL. Appetite suppression and weight loss after the cannabinoid antagonist SR 141716. *Life Sci* 1998;63:PL113–7. [PubMed: 9718088]
149. Hildebrandt AL, Kelly-Sullivan DM, Black SC. Antiobesity effects of chronic cannabinoid CB1 receptor antagonist treatment in diet-induced obese mice. *Eur J Pharmacol* 2003;462:125–32. [PubMed: 12591104]
150. Andersson U, Filipsson K, Abbott CR, Woods A, Smith K, Bloom SR, Carling D, Small CJ. AMP-activated protein kinase plays a role in the control of food intake. *J Biol Chem* 2004;279:12005–8. [PubMed: 14742438]
151. Kola B, Hubina E, Tucci SA, Kirkham TC, Garcia EA, Mitchell SE, Williams LM, Hawley SA, Hardie DG, Grossman AB, Korbonits M. Cannabinoids and ghrelin have both central and peripheral metabolic and cardiac effects via AMP-activated protein kinase. *J Biol Chem* 2005;280:25196–201. [PubMed: 15899896]
152. Theander-Carrillo C, Wiedmer P, Cettour-Rose P, Nogueiras R, Perez-Tilve D, Pfluger P, Castaneda TR, Muzzin P, Schurmann A, Szanto I, Tschoop MH, Rohner-Jeanrenaud F. Ghrelin action in the brain controls adipocyte metabolism. *J Clin Invest* 2006;116:1983–93. [PubMed: 16767221]
153. Kola B, Farkas I, Christ-Crain M, Wittmann G, Lolli F, Amin F, Harvey-White J, Liposits Z, Kunos G, Grossman AB, Fekete C, Korbonits M. The orexigenic effect of ghrelin is mediated through central activation of the endogenous cannabinoid system. *PLoS ONE* 2008;3:e1797. [PubMed: 18335063]
154. Kim SF, Huang AS, Snowman AM, Teuscher C, Snyder SH. From the Cover: Antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase. *Proc Natl Acad Sci U S A* 2007;104:3456–9. [PubMed: 17360666]
155. Nakatsu Y, Kotake Y, Hino A, Ohta S. Activation of AMP-activated protein kinase by tributyltin induces neuronal cell death. *Toxicol Appl Pharmacol*. 2008

156. Croutch CR, Lebofsky M, Schramm KW, Terranova PF, Rozman KK. 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) and 1,2,3,4,7,8-hexachlorodibenzo-p-dioxin (HxCDD) alter body weight by decreasing insulin-like growth factor I (IGF-I) signaling. *Toxicol Sci* 2005;85:560–71. [PubMed: 15703265]
157. Fetissov SO, Huang P, Zhang Q, Mimura J, Fujii-Kuriyama Y, Rannug A, Hokfelt T, Ceccatelli S. Expression of hypothalamic neuropeptides after acute TCDD treatment and distribution of Ah receptor repressor. *Regul Pept* 2004;119:113–24. [PubMed: 15093705]
158. Linden J, Korkalainen M, Lensu S, Tuomisto J, Pohjanvirta R. Effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) and leptin on hypothalamic mRNA expression of factors participating in food intake regulation in a TCDD-sensitive and a TCDD-resistant rat strain. *J Biochem Mol Toxicol* 2005;19:139–48. [PubMed: 15977195]
159. Lee HM, He Q, Englander EW, Greeley GH Jr. Endocrine disruptive effects of polychlorinated aromatic hydrocarbons on intestinal cholecystokinin in rats. *Endocrinology* 2000;141:2938–44. [PubMed: 10919282]
160. de Jesus LA, Carvalho SD, Ribeiro MO, Schneider M, Kim SW, Harney JW, Larsen PR, Bianco AC. The type 2 iodothyronine deiodinase is essential for adaptive thermogenesis in brown adipose tissue. *J Clin Invest* 2001;108:1379–85. [PubMed: 11696583]
161. Alonso A, Marti A, Corbalan MS, Martinez-Gonzalez MA, Forga L, Martinez JA. Association of UCP3 gene -55C>T polymorphism and obesity in a Spanish population. *Ann Nutr Metab* 2005;49:183–8. [PubMed: 16006788]
162. Cha MH, Shin HD, Kim KS, Lee BH, Yoon Y. The effects of uncoupling protein 3 haplotypes on obesity phenotypes and very low-energy diet-induced changes among overweight Korean female subjects. *Metabolism* 2006;55:578–86. [PubMed: 16631432]
163. Herrmann SM, Wang JG, Staessen JA, Kertmen E, Schmidt-Petersen K, Zidek W, Paul M, Brand E. Uncoupling protein 1 and 3 polymorphisms are associated with waist-to-hip ratio. *J Mol Med* 2003;81:327–32. [PubMed: 12756473]
164. van Abeelen AF, de Krom M, Hendriks J, Grobbee DE, Adan RA, van der Schouw YT. Variations in the uncoupling protein-3 gene are associated with specific obesity phenotypes. *Eur J Endocrinol* 2008;158:669–76. [PubMed: 18426825]
165. Fiorito M, Torrente I, De Cosmo S, Guida V, Colosimo A, Prudente S, Flex E, Menghini R, Miccoli R, Penno G, Pellegrini F, Tassi V, Federici M, Trischitta V, Dallapiccola B. Interaction of DIO2 T92A and PPARGgamma2 P12A polymorphisms in the modulation of metabolic syndrome. *Obesity (Silver Spring)* 2007;15:2889–95. [PubMed: 18198294]
166. Festuccia WT, Oztezcan S, Laplante M, Berthiaume M, Michel C, Dohgu S, Denis RG, Brito MN, Brito NA, Miller DS, Banks WA, Bartness TJ, Richard D, Deshaies Y. Peroxisome proliferator-activated receptor-gamma-mediated positive energy balance in the rat is associated with reduced sympathetic drive to adipose tissues and thyroid status. *Endocrinology* 2008;149:2121–30. [PubMed: 18218698]
167. Covaci A, Voorspoels S, Roosens L, Jacobs W, Blust R, Neels H. Polybrominated diphenyl ethers (PBDEs) and polychlorinated biphenyls (PCBs) in human liver and adipose tissue samples from Belgium. *Chemosphere*. 2008
168. Lim JS, Lee DH, Jacobs DR Jr. Association of Brominated Flame Retardants with Diabetes and Metabolic syndrome in the United States Population: 2003-2004. *Diabetes Care*. 2008
169. Hoppe AA, Carey GB. Polybrominated diphenyl ethers as endocrine disruptors of adipocyte metabolism. *Obesity (Silver Spring)* 2007;15:2942–50. [PubMed: 18198302]
170. Ellis-Hutchings RG, Cherr GN, Hanna LA, Keen CL. Polybrominated diphenyl ether (PBDE)-induced alterations in vitamin A and thyroid hormone concentrations in the rat during lactation and early postnatal development. *Toxicol Appl Pharmacol* 2006;215:135–45. [PubMed: 16580039]
171. Kuriyama SN, Wanner A, Fidalgo-Neto AA, Talsness CE, Koerner W, Chahoud I. Developmental exposure to low-dose PBDE-99: tissue distribution and thyroid hormone levels. *Toxicology* 2007;242:80–90. [PubMed: 17964054]
172. Talsness CE, Kuriyama SN, Sterner-Kock A, Schnitker P, Grande SW, Shakibaei M, Andrade A, Grote K, Chahoud I. In utero and lactational exposures to low doses of polybrominated diphenyl

- ether-47 alter the reproductive system and thyroid gland of female rat offspring. *Environ Health Perspect* 2008;116:308–14. [PubMed: 18335096]
173. Yajnik C. Interactions of perturbations in intrauterine growth and growth during childhood on the risk of adult-onset disease. *Proc Nutr Soc* 2000;59:257–65. [PubMed: 10946794]
 174. Hales CN, Barker DJ. The thrifty phenotype hypothesis. *Br Med Bull* 2001;60:5–20. [PubMed: 11809615]
 175. Cottrell EC, Ozanne SE. Developmental programming of energy balance and the metabolic syndrome. *Proc Nutr Soc* 2007;66:198–206. [PubMed: 17466102]
 176. Lisboa PC, Fagundes AT, Denolato AT, Oliveira E, Bonomo IT, Alves SB, Curty FH, Passos MC, Moura EG. Neonatal low-protein diet changes deiodinase activities and pituitary TSH response to TRH in adult rats. *Exp Biol Med (Maywood)* 2008;233:57–63. [PubMed: 18156306]
 177. Moura EG, Santos RS, Lisboa PC, Alves SB, Bonomo IT, Fagundes AT, Oliveira E, Passos MC. Thyroid function and body weight programming by neonatal hyperthyroidism in rats - the role of leptin and deiodinase activities. *Horm Metab Res* 2008;40:1–7. [PubMed: 18197581]
 178. Achard V, Boullu-Ciocca S, Desbriere R, Grino M. Perinatal programming of central obesity and the metabolic syndrome: role of glucocorticoids. *Metab Syndr Relat Disord* 2006;4:129–37. [PubMed: 18370759]
 179. Nyirenda MJ, Lindsay RS, Kenyon CJ, Burchell A, Seckl JR. Glucocorticoid exposure in late gestation permanently programs rat hepatic phosphoenolpyruvate carboxykinase and glucocorticoid receptor expression and causes glucose intolerance in adult offspring. *J Clin Invest* 1998;101:2174–81. [PubMed: 9593773]
 180. Bjorntorp P, Rosmond R. Obesity and cortisol. *Nutrition* 2000;16:924–36. [PubMed: 11054598]
 181. Pasquali R, Vicennati V, Cacciari M, Pagotto U. The hypothalamic-pituitary-adrenal axis activity in obesity and the metabolic syndrome. *Ann N Y Acad Sci* 2006;1083:111–28. [PubMed: 17148736]
 182. Boullu-Ciocca S, Dutour A, Guillaume V, Achard V, Oliver C, Grino M. Postnatal diet-induced obesity in rats upregulates systemic and adipose tissue glucocorticoid metabolism during development and in adulthood: its relationship with the metabolic syndrome. *Diabetes* 2005;54:197–203. [PubMed: 15616029]
 183. Kershaw EE, Morton NM, Dhillon H, Ramage L, Seckl JR, Flier JS. Adipocyte-specific glucocorticoid inactivation protects against diet-induced obesity. *Diabetes* 2005;54:1023–31. [PubMed: 15793240]
 184. Stocker CJ, Arch JR, Cawthorne MA. Fetal origins of insulin resistance and obesity. *Proc Nutr Soc* 2005;64:143–51. [PubMed: 15960859]
 185. Dy J, Guan H, Sampath-Kumar R, Richardson BS, Yang K. Placental 11beta-hydroxysteroid dehydrogenase type 2 is reduced in pregnancies complicated with idiopathic intrauterine growth Restriction: evidence that this is associated with an attenuated ratio of cortisone to cortisol in the umbilical artery. *Placenta* 2008;29:193–200. [PubMed: 18061258]
 186. Odermatt A, Gumy C, Atanasov AG, Dzyakanchuk AA. Disruption of glucocorticoid action by environmental chemicals: potential mechanisms and relevance. *J Steroid Biochem Mol Biol* 2006;102:222–31. [PubMed: 17045799]
 187. Odermatt A, Gumy C. Glucocorticoid and mineralocorticoid action: why should we consider influences by environmental chemicals? *Biochem Pharmacol* 2008;76:1184–93. [PubMed: 18765234]
 188. van Gelderen CE, Bijlsma JA, van Dokkum W, Savelkoul TJ. Glycyrrhizic acid: the assessment of a no effect level. *Hum Exp Toxicol* 2000;19:434–9. [PubMed: 11125713]
 189. Welberg LA, Seckl JR, Holmes MC. Inhibition of 11beta-hydroxysteroid dehydrogenase, the foeto-placental barrier to maternal glucocorticoids, permanently programs amygdala GR mRNA expression and anxiety-like behaviour in the offspring. *Eur J Neurosci* 2000;12:1047–54. [PubMed: 10762336]
 190. Lindsay RS, Lindsay RM, Waddell BJ, Seckl JR. Prenatal glucocorticoid exposure leads to offspring hyperglycaemia in the rat: studies with the 11 beta-hydroxysteroid dehydrogenase inhibitor carbenoxolone. *Diabetologia* 1996;39:1299–305. [PubMed: 8932995]

191. Atanasov AG, Tam S, Rocken JM, Baker ME, Odermatt A. Inhibition of 11 beta-hydroxysteroid dehydrogenase type 2 by dithiocarbamates. *Biochem Biophys Res Commun* 2003;308:257–62. [PubMed: 12901862]
192. Garbrecht MR, Krozowski ZS, Snyder JM, Schmidt TJ. Reduction of glucocorticoid receptor ligand binding by the 11-beta hydroxysteroid dehydrogenase type 2 inhibitor, Thiram. *Steroids* 2006;71:895–901. [PubMed: 16857225]
193. Gumy C, Chandsawangbhuwana C, Dzyakanchuk AA, Kratschmar DV, Baker ME, Odermatt A. Dibutyltin disrupts glucocorticoid receptor function and impairs glucocorticoid-induced suppression of cytokine production. *PLoS ONE* 2008;3:e3545. [PubMed: 18958157]
194. Atanasov AG, Nashev LG, Tam S, Baker ME, Odermatt A. Organotins disrupt the 11beta-hydroxysteroid dehydrogenase type 2-dependent local inactivation of glucocorticoids. *Environ Health Perspect* 2005;113:1600–6. [PubMed: 16263518]
195. Cooke GM, Forsyth DS, Bondy GS, Tachon R, Tague B, Coady L. Organotin speciation and tissue distribution in rat dams, fetuses, and neonates following oral administration of tributyltin chloride. *J Toxicol Environ Health A* 2008;71:384–95. [PubMed: 18246498]
196. Miltenberger RJ, Mynatt RL, Wilkinson JE, Woychik RP. The role of the agouti gene in the yellow obese syndrome. *J Nutr* 1997;127:1902S–1907S. [PubMed: 9278579]
197. Cooney CA, Dave AA, Wolff GL. Maternal methyl supplements in mice affect epigenetic variation and DNA methylation of offspring. *J Nutr* 2002;132:2393S–2400S. [PubMed: 12163699]
198. Weaver IC, Cervoni N, Champagne FA, D'Alessio AC, Sharma S, Seckl JR, Dymov S, Szyf M, Meaney MJ. Epigenetic programming by maternal behavior. *Nat Neurosci* 2004;7:847–54. [PubMed: 15220929]
199. Drake AJ, Walker BR, Seckl JR. Intergenerational consequences of fetal programming by in utero exposure to glucocorticoids in rats. *Am J Physiol Regul Integr Comp Physiol* 2005;288:R34–8. [PubMed: 15178540]
200. Lillycrop KA, Phillips ES, Jackson AA, Hanson MA, Burdge GC. Dietary protein restriction of pregnant rats induces and folic acid supplementation prevents epigenetic modification of hepatic gene expression in the offspring. *J Nutr* 2005;135:1382–6. [PubMed: 15930441]
201. Csaba G, Incze-Gonda A. Transgenerational effect of a single neonatal benzpyrene treatment on the glucocorticoid receptor of the rat thymus. *Hum Exp Toxicol* 1998;17:88–92. [PubMed: 9506259]
202. Oberlander TF, Weinberg J, Papsdorf M, Grunau R, Misri S, Devlin AM. Prenatal exposure to maternal depression, neonatal methylation of human glucocorticoid receptor gene (NR3C1) and infant cortisol stress responses. *Epigenetics* 2008;3:97–106. [PubMed: 18536531]
203. Kaufman D, Banerji MA, Shorman I, Smith EL, Coplan JD, Rosenblum LA, Kral JG. Early-life stress and the development of obesity and insulin resistance in juvenile bonnet macaques. *Diabetes* 2007;56:1382–6. [PubMed: 17470564]
204. Nonogaki K, Nozue K, Oka Y. Social isolation affects the development of obesity and type 2 diabetes in mice. *Endocrinology* 2007;148:4658–66. [PubMed: 17640995]
205. Mokdad AH, Ford ES, Bowman BA, Dietz WH, Vinicor F, Bales VS, Marks JS. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. *Jama* 2003;289:76–9. [PubMed: 12503980]
206. State-specific prevalence of obesity among adults--United States, 2005. *MMWR Morb Mortal Wkly Rep* 2006;55:985–8. [PubMed: 16971886]

Table 1**Endocrine disruptors and pharmaceutical drugs with demonstrated obesogenic properties**

For each class of compound, the known or putative targets are indicated. Possible targets are indicated where some data exist to support a hypothetical mechanism of action.

<i>Obesogen Class</i>	<i>Target</i>			
	Metabolic sensor	Sex steroid dysregulation	Central integration of energy balance	Metabolic set point
<i>Environmental pollutants</i>				
TBT, TPT	PPAR γ , RXRs, TR?	CYP19	PH, HPA?, EC?	GR signaling (11 β -HSD)
Phthalates	PPAR α , PPAR γ	ER	PH?	
BPA	PPAR γ ?, others?	ER? others?	PH?	
PFCs	PPAR γ ?			
PBDEs				HPT
Dithiocarbamates				GR signaling (11 β -HSD)
Alkylphenols		ERs?	NE?	
<i>Nutritional components</i>				
Phytoestrogens		ERs, AR, other?	PH?	?
Glycyrrhetic acid				GR signaling (11 β -HSD)
<i>Pharmaceuticals</i>				
DES		ER		
SSRI			NE?	?
Tricyclic antidepressants			NE?	?
Atypical antipsychotics			NE?, EC	?
TZDs	PPAR γ			HPT?,

TBT – tributyltin, TPT – triphenyltin, BPA – bisphenol A, PFCs – perfluoroalkyl compounds, PBDEs – polybrominated diphenyl ethers, DES – diethylstilbestrol, SSRI – selective serotonin reuptake inhibitor, TZD – thiazolidinediones, NE – neuroendocrine effects, PH – peptidergic hormones, EC – endocannabinoid, HPT – hypothalamus-pituitary-thyroid, HPA – hypothalamus-pituitary-adrenal